MP11-Reumatología
Medicina de Precisión / IBS-MP11 / Consolidado
OBJETIVO DEL GRUPO: Profundizar en la patogenia de la artritis reumatoide. Bases Genético-moleculares de la artritis reumatoide: identificación de marcadores genéticos de predisposición y pronóstico. Destacar su participación en Proyectos Nacionales e Internacionales de financiación competitiva, Colaboración en diferentes proyectos con la SER/FER y de la SAR/FAR, Colaboración en proyectos de financiación competitiva con el Instituto de Parasitología y Biomedicina López-Neyra (CSIC), con Centro de Genómica e Investigación Oncológica (GENyO) y con la Universidad de Granada.
Líneas de investigación
- Biomarcadores de pronóstico y evolución clínica
- Expresión génica en enfermedades autoinmunes
- Factores de respuesta a las terapias biológicas
- Factores pronósticos de evolución y respuesta terapéutica
- Morbilidad cardiovascular
- Polimorfismos en artritis reumatoide
- Riesgo cardiovascular en enfermedades reumatológicas autoinmunes
Redes de investigación
- RIER - Investigación en Inflamación y Enfermedades Reumáticas
ISMAEL FRANCISCO AOMAR MILLAN
INMACULADA JIMENEZ MOLEON
PILAR MORALES GARRIDO
ENRIQUE RAYA ALVAREZ
JUAN SALVATIERRA OSSORIO
RICARDO SANCHEZ PARERA
Evaluating the reliability of cardiovascular risk scales in patients with chronic inflammatory rheumatic diseases
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2025;
FI:4,4; Q1
Periodontitis, Dyslipidemia and Rheumatoid Arthritis: An Additive Model of Cardiovascular Risk
JOURNAL OF CLINICAL MEDICINE, 2025;
FI:2,9; Q1
Clinical ultrasound for the characterisation of obesity: beyond the body mass index
REVISTA CLINICA ESPANOLA, 2025;
FI:1,7; Q2
Nutritional composition, physicochemical, microbiological, and sensory properties of flavored biofermented camel milk containing chickpea milk
ITALIAN JOURNAL OF FOOD SCIENCE, 2025;
FI:3,3; Q2
Association of Combined Anti-Ro52/TRIM21 and Anti-Ro60/SSA Antibodies With Increased Sjögren Disease Severity Through Interferon Pathway Activation
ARTHRITIS & RHEUMATOLOGY, 2024;
FI:11,4; D1
Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort
ANNALS OF THE RHEUMATIC DISEASES, 2024;
FI:20,3; D1
Interferon and B-cell Signatures Inform Precision Medicine in Lupus Nephritis
KIDNEY INTERNATIONAL REPORTS, 2024;
FI:5,7; D1
Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study
LANCET RHEUMATOLOGY, 2024;
FI:15; D1
A Genome-Wide Association Study Suggests New Susceptibility Loci for Primary Antiphospholipid Syndrome
ARTHRITIS & RHEUMATOLOGY, 2024;
FI:11,4; D1
Image in Osteology
REVISTA DE OSTEOPOROSIS Y METABOLISMO MINERAL, 2023;
Molecular typing of canine parvovirus type 2 by VP2 gene sequencing and restriction fragment length polymorphism in affected dogs from Egypt
FRONTIERS IN MICROBIOLOGY, 2023;
FI:6,064; Q1
Characteristics and clinical outcome in 312 patients with moderate to severe pneumonia due to SARS-COV-2 and hyperinflammation treated with anakinra and corticosteroids: A retrospective cohort study
PLOS ONE, 2023;
FI:3,7; Q2
Pregnancy outcomes in 1869 pregnancies in a large cohort from the Spanish Society of Rheumatology Lupus Register (RELESSER)
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2023;
FI:5; Q2
Real-World Persistence and Treatment Patterns in Patients with Psoriatic Arthritis Treated with Anti-IL17 Therapy in Spain: The PerfIL-17 Study
ADVANCES IN THERAPY, 2023;
FI:3,8; Q3
Hospitalization and mortality from COVID-19 of patients with rheumatic inflammatory diseases in Andalusia
REUMATOLOGIA CLINICA, 2022;
Dose-Dependent Effect of Melatonin on BAT Thermogenesis in Zucker Diabetic Fatty Rat: Future Clinical Implications for Obesity
ANTIOXIDANTS, 2022;
FI:7,675; D1
Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients
RHEUMATOLOGY, 2022;
FI:7,046; Q1
Biologic therapy in refractory neurobehcet’s disease: a multicentre study of 41 patients and literature review
RHEUMATOLOGY, 2022;
FI:7,046; Q1
Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia
MEDICINA CLINICA, 2022;
FI:3,2; Q2
A new molecular classification to drive precision treatment strategies in primary Sjogren’s syndrome.
NATURE COMMUNICATIONS, 2021;
FI:14,919; D1
Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases.
ARTHRITIS & RHEUMATOLOGY, 2021;
FI:10,995; D1
Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study
INTERNAL AND EMERGENCY MEDICINE, 2021;
FI:3,397; Q2
Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply..
INTERNAL AND EMERGENCY MEDICINE, 2021;
FI:3,397; Q2
Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021;
FI:4,473; Q2
Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients
RHEUMATOLOGY, 2020;
FI:5,606; Q1
Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER)
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2020;
FI:4,751; Q1
Bacteremia in Systemic Lupus Erythematosus in Patients from a Spanish Registry: Risk Factors, Clinical and Microbiological Characteristics, and Outcomes
JOURNAL OF RHEUMATOLOGY, 2020;
FI:3,35; Q2
Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality
LUPUS, 2020;
FI:2,251; Q3
Differences in clinical manifestations and increased severity of systemic lupus erythematosus between two groups of Hispanics: European Caucasians versus Latin American mestizos (data from the RELESSER registry)
LUPUS, 2020;
FI:2,251; Q3
Identification of a 3 ‘-Untranslated Genetic Variant of RARB Associated With Carotid Intima-Media Thickness in Rheumatoid Arthritis: A Genome-Wide Association Study
ARTHRITIS & RHEUMATOLOGY, 2019;
FI:9,002; D1
Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behcet’s Disease: National Multicenter Study of 177 Cases
ARTHRITIS & RHEUMATOLOGY, 2019;
FI:9,002; D1
Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2019;
FI:5,072; Q1
Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept
PLOS ONE, 2019;
FI:2,776; Q2
Molecular Characterization of Monocyte Subsets Reveals Specific and Distinctive Molecular Signatures Associated With Cardiovascular Disease in Rheumatoid Arthritis
FRONTIERS IN IMMUNOLOGY, 2019;
FI:4,716; Q2
Cross-phenotype analysis of Immunochip data identifies KDM4C as a relevant locus for the development of systemic vasculitis
ANNALS OF THE RHEUMATIC DISEASES, 2018;
FI:12,35; D1
Association of a rare variant of the TNFSF13B gene with susceptibility to Rheumatoid Arthritis and Systemic Lupus Erythematosus
SCIENTIFIC REPORTS, 2018;
FI:4,122; Q1
Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis
PLOS ONE, 2018;
FI:2,766; Q1
The beliefs of rheumatoid arthritis patients in their subcutaneous biological drug: strengths and areas of concern
RHEUMATOLOGY INTERNATIONAL, 2018;
FI:1,952; Q4
The beliefs of rheumatoid arthritis patients in their subcutaneous biological drug: strengths and areas of concern (vol 38, pg 1735, 2018)
RHEUMATOLOGY INTERNATIONAL, 2018;
FI:1,952; Q4
A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis
AMERICAN JOURNAL OF HUMAN GENETICS, 2017;
FI:9,025; D1
Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project
JOURNAL OF CLINICAL LIPIDOLOGY, 2017;
FI:5,812; D1
Increased expression of microRNA-155 in peripheral blood mononuclear cells from psoriasis patients is related to disease activity
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017;
FI:3,528; Q1
Influence of coronary artery disease and subclinical atherosclerosis related polymorphisms on the risk of atherosclerosis in rheumatoid arthritis
SCIENTIFIC REPORTS, 2017;
FI:4,259; Q1
Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2017;
FI:4,498; Q1
IFI44L promoter methylation as a blood biomarker for systemic lupus erythematosus
ANNALS OF THE RHEUMATIC DISEASES, 2016;
FI:12,384; D1
Influence of elevated-CRP level-related polymorphisms in non-rheumatic Caucasians on the risk of subclinical atherosclerosis and cardiovascular disease in rheumatoid arthritis
SCIENTIFIC REPORTS, 2016;
FI:5,228; Q1
Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry
RHEUMATOLOGY, 2016;
FI:4,524; Q1
Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis
PHARMACOGENOMICS JOURNAL, 2016;
FI:3,784; Q1
Tacrolimus-induced gynecomastia in a patient with polymyositis
MEDICINA CLINICA, 2016;
FI:1,267; Q2
Estudio prospectivo de varios países, de la vida real, de varios grupos sobre la persistencia del tratamiento con risankizumab en la artritis psoriásica (PERIS)
Financiador: ABBVIE SPAIN S.L.U.
Tipo de prueba: ESTUDIO OBSERVACIONAL CON MEDICAMENTOS
Tiempo de ejecución: 31/01/2025 - 28/02/2029
IP: PILAR MORALES GARRIDO
Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de belimumab administrado por vía subcutánea en adultos con enfermedad pulmonar intersticial (EPI) asociada a enfermedad del tejido conectivo (ETC)
Financiador: GLAXOSMITHKLINE, S.A.
Tipo de prueba: ENSAYO CLÍNICO CON MEDICAMENTOS
Tiempo de ejecución: 07/08/2024 - 30/12/2028
IP: ENRIQUE RAYA ALVAREZ
Efectividad en la vida real de upadacitinib para el alivio temprano y sostenido del dolor en la espondiloartritis axial radiográfica (UPSTAND)
Financiador: ABBVIE SPAIN S.L.U.
Tipo de prueba: ESTUDIO OBSERVACIONAL CON MEDICAMENTO
Tiempo de ejecución: 16/03/2023 - 30/06/2025
IP: ENRIQUE RAYA ALVAREZ
Estudio de fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de pegozafermina en pacientes con hipertrigliceridemia grave (HTGG). ENTRUST
Financiador: 89BIO INC
Tipo de prueba: ENSAYO CLÍNICO CON MEDICAMENTOS
Tiempo de ejecución: 12/09/2023 - 30/12/2024
IP: ISMAEL FRANCISCO AOMAR MILLAN
“Estudio prospectivo aleatorizado, multicéntrico, para comparar la eficacia a 52 semanas (1 año) de teriparatida biosimilar y alendronato en la prevención de nuevas fracturas vertebrales morfométricas y/o agravamiento de fracturas vertebrales previas en mujeres con fractura vertebral clínica o fractura de cadera reciente (riesgo inminente de fractura) y baja densidad mineral ósea. Estudio IMMINENT
Financiador: GEDEON RICHTER IBÉRICA S.A.
Tipo de prueba: ENSAYO CLINICO COMERCIAL
Tiempo de ejecución: 14/06/2022 - 30/12/2023
IP: ENRIQUE RAYA ALVAREZ
Un estudio multinacional, no intervencionista de tofacitinib en pacientes tratados para la artritis psoriásica. TOPSATI. PFI-TOF-2020-01
Financiador: PFIZER HOLDING FRANCE
Tipo de prueba: ESTUDIO OBSERVACIONAL CON MEDICAMENTO
Tiempo de ejecución: 03/08/2022 - 30/01/2024
IP: ENRIQUE RAYA ALVAREZ
Evaluación de guselkumab (Tremfya®) y el tratamiento con distintos inhibidores de la IL-17 en pacientes con artritis psoriásica en la práctica clínica habitual; estudio de cohortes, observacional y prospectivo.
Financiador: JANSSEN-CILAG INTERNATIONAL N.V.
Tipo de prueba: ESTUDIO POSAUTORIZACION COMERCIAL
Tiempo de ejecución: 19/11/2021 - 30/10/2027
IP: ENRIQUE RAYA ALVAREZ
PsA Biológicos: Estudio observacional retrospectivo sobre los patrones de tratamiento anti-IL17 en el manejo de la artritis psoriásica. LIL-IXE-2020-01 (LY2439821)
Financiador: LILLY, S.A.
Tipo de prueba: ESTUDIO POSAUTORIZACION COMERCIAL
Tiempo de ejecución: 06/10/2020 - 30/01/2021
IP: ENRIQUE RAYA ALVAREZ
Estudio observacional de la persistencia del tratamiento en la artritis psoriasica Estudio PRO-SPIRIT. (LIL-IXE-2019-01)
Financiador: ELI LILLY AND COMPANY
Tipo de prueba: ESTUDIO POSAUTORIZACION COMERCIAL
Tiempo de ejecución: 20/10/2020 - 30/12/2025
IP: ENRIQUE RAYA ALVAREZ